Public Reporting

ACO Name & Location

Emergent ACO, LLC
2323 N. John B Dennis Hwy
Kingsport, TN 37660

ACO Primary Contact

Primary Contact Name: Scott R. Fowler, J.D., M.D.
Primary Contact Phone: 423-857-2091
Primary Contact Email: scott.fowler@myhmg.com

ACO Governing Body:

PY 2025

Member Member's Voting
Power – Expressed as
a Percentage or Number
Membership Type ACO Participant
Legal Business
Name/DBA, if
Applicable
Last Name First Name Title/Position
Fowler, J.D., M.D. Scott Director/President 6.25% ACO Participant Representative Holston Medical Group, PC
Hager, M.D. Shelton Director 6.25% ACO Participant Representative Holston Medical Group, PC
Moye David Director 6.25% ACO Participant Representative RDMG Associates, PA
Wenzlik, M.D. Adam Director 6.25% ACO Participant Representative RDMG Associates, PA
Delay, M.D. Eric Director 6.25% ACO Participant Representative HealthStar Physicians, PC
McNabney, M.D. David Director 6.25% ACO Participant Representative HealthStar Physicians, PC
Tondo, M.D. Lewis Director 6.25% ACO Participant Representative Iredell Physician Network, LLC
Green John Director 6.25% ACO Participant Representative Iredell Physician Network, LLC
Ajjan, M.D. Madhi Director 6.25% ACO Participant Representative Optimed Hospitalists
Ibanez, PA Alicia Director 6.25% ACO Participant Representative Optimed Hospitalists
Hopland, M.D. Kenneth Director 6.25% ACO Participant Representative Medical Care, PLLC
Hopland Steve Director 6.25% ACO Participant Representative Medical Care, PLLC
Kauffman, M.D. Michael Director 6.25% ACO Participant Representative Taos Medical Group, PA
Friedman, M.D. Neal Director 6.25% Medicare Beneficiary Representative Medicare Beneficiary Representative
Blanken Vickey Director 6.25% Community Stakeholder Highlands Physicians, Inc.
Sizemore Samantha Director 6.25% Other OnePartner Health Solutions, LLC
Key ACO Clinical & Administrative Leadership:

ACO Executive: Scott R. Fowler, J.D., M.D.
Medical Director: Shelton L. Hager, M.D.
Compliance Officer: Cheryl Stanski, M.D.
Quality Assurance/Improvement Officer: Samantha Sizemore, COO

Associated Committees & Committee Leadership:

Committee Name Committee Leader Name and Position
Clinical Transformation Committee Shelton Hager, M.D. - Committee Chair
Operations, Quality, Clinical Process, and Population Health Improvement Committee Samantha Sizemore, COO - Committee Chair
Beneficiary Engagement Committee Samantha Sizemore, COO - Committee Chair
Communications & Marketing Committee Samantha Sizemore, COO - Committee Chair
Technology & Data Analytics Committee Byron Sayler - Committee Chair
Contracting & Finance Committee Shawna Armstrong, Treasurer - Committee Chair
Compliance Committee Cheryl Stanski, M.D. - Committee Chair
Types of ACO Participants, or Combinations of Participants, that Formed the ACO:
  • Networks of individual practices of ACO professionals
Shared Savings and Losses
Amount of Shared Savings/Losses
  • Fifth Agreement Period
    • Performance Year 2023 - January 1, 2023 - December 31, 2023, $13,329,960.66
  • Fourth Agreement Period
    • Performance Year 2022 - January 1, 2022 - December 31, 2022, $10,221,401.17
  • Third Agreement Period
    • Performance Year 2021 - January 1, 2021 – December 31, 2021, $8,290,400.71
  • Second Agreement Period
    • Performance Year 2020 - January 1, 2020 – December 31, 2020, $8,679,219.81
  • First Agreement Period
    • Performance Year 2019 A - July 1, 2019 – December 31, 2019, $3,289,869.51

Note: Our ACO participated in multiple performance years during Calendar Year 2019. Shared savings/losses amount reported for Performance Year 2019, therefore represents net shared savings or losses across all performance years in 2019 and is shown under all agreement periods in which the ACO operated during Calendar Year 2019.

Shared Savings Distribution
  • Fifth Agreement Period

    • Performance Year 2023 - January 1, 2023 - December 31, 2023
      • Proportion invested in infrastructure: 0%
      • Proportion invested in redesigned care processes/resources: 25%
      • Proportion of distribution to ACO participants: 75%
  • Fourth Agreement Period

    • Performance Year 2022 - January 1, 2022 - December 31, 2022
      • Proportion invested in infrastructure: 0%
      • Proportion invested in redesigned care processes/resources: 20%
      • Proportion of distribution to ACO participants: 80%
  • Third Agreement Period

    • Performance Year 2021 – January 1, 2021 – December 31, 2021
      • Proportion invested in infrastructure: 0%
      • Proportion invested in redesigned care processes/resources: 20%
      • Proportion of distribution to ACO participants: 80%
  • Second Agreement Period
    • Performance Year 2020 - January 1, 2020 – December 31, 2020
      • Proportion invested in infrastructure: 0%
      • Proportion invested in redesigned care processes/resources: 20%
      • Proportion of distribution to ACO participants: 80%
  • First Agreement Period
    • Performance Year 2019A – July 1, 2019 – December 31, 2019
      • Proportion invested in infrastructure: 0%
      • Proportion invested in redesigned care processes/resources: 0%
      • Proportion of distribution to ACO participants: 100%

    Note: Our ACO participated in multiple performance years during Calendar Year 2019. Shared savings/losses amount reported for Performance Year 2019, therefore represents net shared savings or losses across all performance years in 2019 and is shown under all agreement periods in which the ACO operated during Calendar Year 2019.

    2023 Quality Performance Results:
    ACO Quality
    Measure Number
    Measure Name Rate ACO Mean
    001 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) [1] 9.15 9.84
    134 Preventive Care and Screening: Screening for Depression and Follow-up Plan 91.56 80.97
    236 Controlling High Blood Pressure 87.28 77.80
    318 Falls: Screening for Future Fall Risk 95.75 89.42
    110 Preventive Care and Screening: Influenza Immunization 96.59 70.76
    226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention 100.00 79.29
    113 Colorectal Cancer Screening 81.51 77.14
    112 Breast Cancer Screening 85.14 80.36
    438 Statin Theraphy for the Prvention and Treatment of Cardiovascular Disease 81.34 87.05
    370 Depression Remission at Twelve Months 11.11 16.58
    321 CAHPS for MIPS 6.95 6.25
    479 Hospital Wide 30 Day, All-Cause Readmission HWR Rate for MIPS Groups 0.1572 0.1553
    484 Clinician and Clinician Group Risk-standardized Hospital Admission Rates for Patients with Multiple Chronic Conditions [1] - 35.89
    CAPHS Number Measure Name Rate ACO Mean
    CAHPS-1 Getting Timely Care, Appointments, and Information 82.20 83.68
    CAHPS-2 How Well Providers Communicate 94.25 93.69
    CAHPS-3 Patient’s Rating of Provider 92.67 92.14
    CAHPS-4 Access to Specialists 76.32 75.97
    CAHPS-5 Health Promotion and Education 62.18 63.93
    CAHPS-6 Shared Decision Making 64.22 61.60
    CAHPS-7 Health Status and Functional Status 75.36 74.12
    CAHPS-8 Care Coordination 86.68 85.77
    CAHPS-9 Courteous and Helpful Office Staff 93.00 92.31
    CAHPS-11 Stewardship of Patient Resources 31.10 26.69

    Please also note that per CMS policy, you should not publicly share or report cell sizes <11 or any combination of information that would allow cell sizes of <11 to be calculated.

    Payment Rule Waivers
    • Waiver for Payment for Telehealth Services:
      • Our ACO clinicians provide telehealth services using the flexibilities under 42 CFR § 425.612(f) and 42 CFR § 425.613.
    • Fraud and Abuse Waivers
      • ACO Pre-Participation Waiver:
        The following information describes each arrangement for which our ACO seeks protection under the ACO
        Pre-Participation Waiver, including any material amendment or modification to a disclosed arrangement.

        • Parties to the arrangement: Emergent ACO, LLC and Quest Diagnostics, Inc.
        • Date of arrangement: 03/16/2018
        • Items, services, goods, or facility provided: Services
        • No Amendments
        • Summary of Arrangement Conducted Under the Medicare ACO Pre-Participation Waiver
      • ACO Participation Waiver:
        The following information describes each arrangement for which our ACO seeks protection under the ACO
        Participation Waiver, including any material amendment or modification to a disclosed arrangement.

        • Parties to the arrangement: Emergent ACO, LLC and Quest Diagnostics, Inc.
        • Date of arrangement: 02/01/2019
        • Items, services, goods, or facility provided: Services
        • No Amendments
        • Summary of Arrangement Conducted Under the Medicare ACO Participation Waiver

    Last updated on November 27, 2024